Results 141 to 150 of about 189,087 (191)

Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE). [PDF]

Eye (Lond)
Wijesingha N, Kotecha A, Margaron P, Sivaprasad S.   +3 more
europepmc   +1 more source

Switching to Intravitreal Brolucizumab after Ranibizumab or Aflibercept Using Treat and Extend Regimen for Neovascular Age-Related Macular Degeneration in Japanese Patients: 1-Year Results and Factors Associated with Treatment Responsiveness. [PDF]

J Clin Med
Hirayama K, Yamamoto M, Honda S, Kyo A, Misawa N, Kohno T.   +5 more
europepmc   +1 more source

Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema: The Vitrectomy in Diabetic Macular Oedema (VIDEO) Randomized Clinical Trial.

JAMA Ophthalmol
Maguire MJ, Laidlaw A, Hammond C, Muqit MMK, Steel D, Dinah C, Lee E, Hillier R, Almeida G, Hussain R, Gordon-Bennet P, Hughes E, Alexander P, Vaideanu-Collins D, Jackson T.   +14 more
europepmc   +1 more source

Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials [PDF]

core   +1 more source

Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study. [PDF]

Int J Retina Vitreous
Kanadani T, Rabelo N, Takahashi D, Magalhães L, Farah M.   +4 more
europepmc   +1 more source

Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy [PDF]

British Journal of Ophthalmology, 2018
AimTo assess the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy in eyes with macular diseases.MethodsIn this prospective study, consecutive subjects received intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections for various macular diseases. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the
Ahmad M, Mansour, Abdulrazzak, Charbaji, Michel Eid, Farah, Hana A, Mansour, Jay, Chhablani   +4 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION

Retina, 2016
To evaluate the effects of aflibercept therapy using a treat-and-extend regimen on treatment-naïve retinal angiomatous proliferation (RAP) and development of retinal pigment epithelium (RPE) atrophy.We retrospectively studied 17 treated eyes with RAP and 13 untreated fellow eyes.
Hidetaka, Matsumoto, Taku, Sato, Masahiro, Morimoto, Ryo, Mukai, Maki, Takahashi, Takashi, Hiroe, Kensuke, Ehara, Mayuko, Takayama, Kensuke, Mimura, Shoji, Kishi   +9 more
openaire   +2 more sources

Giant ancient schwannoma of pancreatic head treated by extended pancreatoduodenectomy

Pancreatology, 2004
We report a case of a 55-year-old woman who was transferred from another center to our university clinic after diagnostic laparotomy with a pancreatic head tumor which was seen to encase the portal vein. Although intraoperative biopsies were performed, a histologic diagnosis of the tumor was not possible before giving suspect to a malignant tumor being
Dobschütz, Ernst von, Walch, Axel Karl, Werner, Martin, Hopt, Ulrich T., Adam, Ulrich   +4 more
openaire   +3 more sources

Treat-and-extend therapy with aflibercept for diabetic macular edema: a prospective clinical trial

Japanese Journal of Ophthalmology, 2021
To investigate the efficacy and safety of a treat-and-extend (T&E) regimen using aflibercept (Eylea) for diabetic macular edema (DME).Prospective, open-label, multicenter, single-arm, nonblinded clinical study.Forty eyes of 40 patients with DME received a T&E regimen of intravitreal aflibercept injection (IAI) with the longest treatment interval set to
Takao, Hirano, Yuichi, Toriyama, Yoshihiro, Takamura, Masahiko, Sugimoto, Taiji, Nagaoka, Yoshimi, Sugiura, Fumiki, Okamoto, Michiyuki, Saito, Kousuke, Noda, Shigeo, Yoshida, Akihiro, Ishibazawa, Osamu, Sawada, Toshinori, Murata   +12 more
openaire   +2 more sources

The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK

Advances in Therapy, 2016
Wet age-related macular degeneration (AMD) is a chronic eye condition that causes severe deterioration of vision and even blindness. Current wet AMD treatment in the UK involves the vascular endothelial growth factor inhibitors ranibizumab and aflibercept.
Wrik, Ghosh, Rose, Wickstead, Lindsay, Claxton, Jeanette, Kusel, Matthew, Taylor, Kelly, Fleetwood, Ruth, Pulikottil-Jacob   +6 more
openaire   +2 more sources